Penn Pharma Celebrates 4 Years Accident Free
Pharmaceutical manufacturer Penn Pharma, a PCI company, has reached another significant safety milestone this month having operated for four years without a single accident at its facility in Tredegar, South Wales.
This landmark equates to 2.4 million working hours worked by approximately 300 staff and is a record that Penn, now a PCI company, is extremely proud of. Backed by a recent ISO14001 re-certification, the company places equal emphasis on its environmental management system and compliance.
To achieve this record in a standard day-to-day operational environment would be remarkable; however it is even more significant given the substantial expansion programmes undertaken at the site in the last 4 years. First, there was the design and build of the new contained manufacturing facility for the development and manufacturing of highly potent compounds which completed in September 2013, followed by a further capacity expansion resulting in a new large-scale commercial manufacturing suite which became operational in June 2014. Both expansion programmes were completed in less than 12 months, but not at the expense of safety.
To undertake such significant construction programmes while maintaining operational functionality elsewhere in the site and still remain accident free is a truly remarkable achievement and one of which the company and its employees are extremely proud.
Commenting on this latest milestone, Mark Dean-Netscher Vice President, International Operations said: “This type of achievement in safety does not just happen; we have created a safety focused culture by developing robust processes including a very effective ’near miss’ system. When we talk about safety within the business, there is a real sense of pride evident and it is the commitment of our staff which has led to this incredible achievement.”
Mark continued: “Customers can be confident that with this industry benchmark, Penn is uniquely placed as an outsourcing partner. We offer a guaranteed ‘safe pair of hands’ in the extended supply chain.”
This latest announcement is just one of a long list of achievements enjoyed by Penn in recent months; in 2014 Penn won the Facility Integration category at the ISPE Facility of the Year for its new contained manufacturing facility, as well as being awarded three CMO Leadership Awards.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance